Smart sensors could revolutionize MG monitoring
NCT ID NCT07226830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether wearable sensors and smartphone apps can accurately track symptoms of generalized myasthenia gravis (gMG) in 25 people starting treatment with VYVGART. Participants wear sensors to measure activity, speech, and fatigue over 16 weeks. The goal is to see if digital tools can replace some clinic visits for monitoring disease changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that wearable sensors reliably monitor MG symptoms at home, potentially improving remote care and reducing clinic visits.
- What could go wrong
- This is a small, early observational study (25 people) focused on feasibility, not treatment effectiveness. Results may not apply to all MG patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital, Neuromuscular Diagnostic Center
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at myasthenia gravis
- Can tracking daily life unlock myasthenia gravis mysteries?
- Miniature Nerve-Muscle models may reveal why some myasthenia gravis patients Don't improve
- New drug aims to ease daily struggles of myasthenia gravis
- Engineered immune cells take on rare Muscle-Weakening disease
- New drug aritinercept aims to tame myasthenia gravis symptoms